1	Unipolar voltage for better characterizing left atrium substrates: Comparing
2	the predictive efficacy for recurrence post atrial fibrillation ablation in a
3	post-hoc analysis of STABLE-SR-III
4	
5	Running title: Unipolar Voltage for recurrence prediction
6	
7	Xiuyu Qi, MD, Hongwu Chen, MD, Gang Yang, MD, Mingfang Li, MD, Kai Gu, MD, Hailei Liu, MD,
8	Zidun Wang, MD, Xiaohong Jiang, MD, Chang Cui, MD, Cheng Cai, MD, Minglong Chen, MD,
9	Weizhu Ju, MD
10	
11	The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, China
12	
13	Correspondence to:
14	Weizhu Ju, MD,
15	Division of Cardiology, the First Affiliated Hospital with Nanjing Medical University, Guangzhou Road
16	300, Nanjing, 210029, China.
17	Tel: $0086-25-68303115$ Fax: $0086-25-6813-6479$
18	E-mail: juweizhu@126.com
19	Minglong Chen, MD, Division of Condialogy the First Affiliated Hagnital of Naniing Medical University Cuanarhay Bood
20 21	200 Nanjing 210020 China
21 22	500, Nanjing, 210029, China. Tel: 0086-25-68303116 Fax:0086-25-6813-6470
22 23	Final: $chenminglong@nimu.edu.cn$
23 24	
25	Total word count: 4773
26	
27	
28	
20	
29	
30	
31	
~-	
32	
33	NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

34 35	Abstract
36	Background
37	Intracardiac mapping has become a prevalent technique for assessing cardiac fibrosis. While
38	bipolar recording is universally acknowledged as an indicator of cardiomyocyte activation,
39	unipolar recording has emerged as an alternative technique due to its advantage of providing a
40	wider field of view. This study aims to compare the efficacy of unipolar voltage (UV) versus
41	bipolar voltage (BV) in predicting recurrence in elderly atrial fibrillation patients.
42	Methods
43	In Substrate Ablation in the Left Atrium during Sinus Rhythm Trial III, 414 patients were
44	enrolled in the modified intention-to-treat analysis. Of them, 375 patients who completed the
45	follow-up with preserved mapping data were included in the analysis. For each patient, the
46	mean UV and BV was obtained from the electrograms sampled in left atrium (LA).
47	Results
48	Both low UV and BV of LA had significant associations with the long-term recurrence of
49	atrial tachyarrhythmia (ATa). At the same time, only mean UV was independently associated
50	with the outcome. The model by UV with ablation feature had higher discriminatory power to
51	predict ATa recurrence compared with BV model (AUC: 0.858 vs 0.757, P<0.001). Decision
52	curve analysis demonstrates that UV model provides larger net benefit across the range of
53	reasonable threshold probabilities between 0% and 70% compared with BV model between 0% $$
54	and 45%. In subgroup analysis, UV reveals more powerful predictive efficacy compared with
55	BV, with the AUC 0.843 vs. 0.751 (P=0.0008) in CPVI alone cohort and 0.882 vs. 0.750
56	(P=0.0004) in CPVI plus cohort, respectively.

57 **Conclusion**

58 UV exhibits a higher efficacy for predicting long-term ATa recurrence after ablation

59	compared with BV in elderly patients with atrial fibrillation. The superiority exists regardless
60	of whether the patient accepts substrate modification. The outcome suggests that unipolar
61	recording may better characterize LA fibrosis by capturing more comprehensive transmural
62	features than bipolar signals.
63	
64	Clinical Trial Registration:
0.5	

65 ClinicalTrials.gov; URL: https://www.clinicaltrials.gov. Unique Identifier: NCT03462628

67 Clinical perspective

68 What's known

- 69 Atrial fibrosis represents a central pathophysiological feature and has been correlated with
- 70 complications and resistance to drug and ablation therapy for atrial fibrillation. Evaluating
- 71 the degree of fibrosis holds paramount clinical importance.
- 72 Contact intracardiac mapping stands out as a common method for assessing fibrosis. The
- 73 amplitude of bipolar electrogram signifies the activation of viable cardiomyocytes.
- 74 Moreover, the decline in amplitude of bipolar voltage has been confirmed to be associated
- 75 with the long-term recurrence after ablation.

76 What the study adds

- In comparison to bipolar voltage, endocardial mean unipolar voltage of left atrium exhibits
 a higher efficacy for predicting recurrence after ablation in elderly patients with atrial
 fibrillation.
- The superiority predictive ability of unipolar mapping suggests its advantage of providing
 a broader, more penetrative field of view, enabling the identification of arrhythmogenic
 substrates in deeper layers of the atrium.
- 83
- 84
- 85
- 86

87

88

89 Non-standard Abbreviations and Acronyms:

- 90 AF: atrial fibrillation
- 91 ATa: atrial tachyarrhythmia
- 92 BV: bipolar voltage
- 93 CI: confidence interval
- 94 CPVI: circumferential pulmonary vein isolation
- 95 OR: odds ratio
- 96 LA: left atrium
- 97 LAD: left atrial diameter
- 98 LVA: low-voltage area
- 99 UV: unipolar voltage

101 Introduction

Atrial fibrillation (AF) is one of the most prevalent arrhythmias¹. Atrial fibrosis has been 102 established as the central pathophysiological feature and has been associated with 103 complications and resistance to drug and ablation therapy for AF²⁻⁴. Consequently, evaluating 104 the degree of fibrosis holds significant importance for therapeutic decision-making and 105 prognosis assessment⁵. Contact intracardiac mapping using electrodes has emerged as a 106 clinically accessible modality for fibrosis evaluation. The amplitude of the bipolar electrogram 107 indicates the activation of viable cardiomyocytes. In clinical practice, low voltage area (LVA) 108 identified through endocardial bipolar mapping is generally regarded as indicative of atrial 109 fibrotic regions⁵⁻⁷. Despite this, several publications had raised concerns about the "field-of-110 view" of bipolar electrograms, highlighting the inherent limitation of being unable to detect 111 transmural substrates⁸. 112

Unipolar voltage (UV) mapping provides a distinct perspective and potential⁹⁻¹¹. With its 113 broader, more penetrative field of view, UV mapping can identify arrhythmogenic substrates 114 in deeper layers of the heart⁸. From this point of view, we hypothesized that atrial UV may 115 reflect more comprehensive transmural information regarding atrial substrates in patients with 116 AF. Consequently, it could potentially offer a more robust prediction for the recurrence of 117 patients who undergo ablation. In this post-hoc analysis of Substrate Ablation in the Left 118 Atrium during Sinus Rhythm Trial III (STABLE-SR III)⁷, we examined the predictive efficacy 119 of UV versus BV for the long-term control of atrial arrythmia (ATa) in elder patients with 120 121 paroxysmal AF.

123 Methods

124 Study design and population

The study design of STABLE-SR-III (Substrate Ablation in the Left Atrium during Sinus 125 Rhythm Trial III; ClinicalTrials.gov; URL: https://www.clinicaltrials.gov. Unique Identifier: 126 NCT03462628) trial, have been published previously. Between April 1, 2018 and August 3, 127 2020, 65 to 80-year-old patients with paroxysmal AF were recruited for catheter ablation in 14 128 centers across mainland China. The inclusion and exclusion criteria adhere to the main study. 129 A straightforward computerized randomization method is employed to assign patients to either 130 131 the circumferential pulmonary vein isolation (CPVI) alone or CPVI plus low-voltage-area ablation arm in a 1:1 ratio. In the study group, additional ablation procedures were carried out 132 beyond CPVI. These procedures encompassed the homogenization of LVAs, defragmentation 133 134 in the transitional zones, and, if required, de-channeling was performed. In the CPVI alone group, a comprehensive voltage mapping was meticulously conducted during sinus rhythm 135 without any supplementary ablation procedures. 136

137 The STABLE-SR-III trial was approved by the Institutional Review Broad of the First 138 Affiliated Hospital of Nanjing Medical University and each participating site. A written 139 informed consent was obtained from all patients.

140 Sampling of the points and evaluation of the voltage

After CPVI, by using Thermocool SmartTouch and CARTO3 System (Biosense Webster, Inc., Diamond Bar, CA, USA), a detailed left atrium (LA) voltage map was created point by point under sinus rhythm. To ensure the accuracy of mapping, a contact force with over 5 g

144 was mandatory, and at least 150 surface points should be sampled.

The BV and UV values were automatically determined and provided by the CARTO 3 system. All voltage values for all mapped points were collected offline and exported from the system. The mean voltage was calculated based on all values of the mapped points.

148 Study endpoints

The primary endpoint of this study aimed to assess the freedom of any ATa without the need for antiarrhythmic drugs following a single-ablation procedure. Recurrence was specifically defined as an episode of ATa occurring beyond the 90-day blanking period and lasting longer than 30 seconds. The occurrence of ATa in the first three months after the index ablation (the blanking period) was not counted. The episodes of ATa were confirmed through a blinded review by two senior electrophysiologists.

155 Statistical analysis

156 The long-term clinical outcomes (up to 23 months) were compared between BV-based model and UV-based model. Continuous data were presented as mean \pm standard deviation. Group 157 comparisons were performed using an independent sample t-test or Mann-Whitney U 158 nonparametric test. Classification data were expressed as frequency or rate (%), and 159 comparison between groups was performed by Pearson $\gamma 2$ test method. The logistic regression 160 test was performed using AF recurrence as the dependent variable. The receiver operating 161 characteristic curve (ROC) and area under curve (AUC) was calculated to compare the 162 discriminatory capability among the models and quantify the discrimination ability. Statistical 163 differences in the AUCs were compared using the Delong test. The clinical utility of the model 164 was evaluated by decision curve analysis. The calibration curve was plotted using a bootstrap 165 resampling method (1000 bootstrap resamples), and the Hosmer and Lemeshow test was 166

performed. A two-sided p value less than 0.05 was considered statistically significant. Data
processing and analysis were performed using R version 4.3.0(http://www.R-project.org/) and
SPSS, version 25.

170

171 **Results**

172 Baseline characteristics

438 patients were enrolled between April 1, 2018, and August 3, 2020, and were randomly 173 assigned to receive CPVI plus LVA ablation (n=219) or CPVI alone (n=219). Among them, 174 175 414 patients were enrolled in the modified intention-to-treat analysis, and 405 patients completed follow-up. Of the 405 patients completed follow-up, thirty patients were not 176 included in the study due to the raw data hard disk error. Therefore, a total of 375 patients were 177 178 included in the present study, with a mean age of 70.41±4.28 years and 52% of male (Table 1). There was no statistically significant difference between the patients included and excluded 179 regarding the clinical characteristics and the group features (Supplement Table 1). 180

181 Model development

The variables significantly associations with the long-term freedom from ATa were assessed by the univariate logistic regression and are shown in Table 2. Independent predictors were identified with use of stepwise multivariable analysis of logistic regression (Table 3). BV (OR= 0.18, 95%CI=0.10-0.33, P<0.001), a risk factor in univariable regression analysis, loses significance (BV in multivariate regression: OR=0.87, 95%CI=0.35-2.14, P=0.755) once UV (OR=0.12, 95% CI=0.06-0.25, P<0.001) is included in the multifactorial regression (Table 3). The adjusted predictive values for the recurrence of AF in relation to mean UV and BV are

presented in Table 4. In the unadjusted model, UV (OR= 0.12, 95%CI=0.07-0.21, P<0.001) demonstrated better predictive recurrence effects and potential benefits when compared to BV (OR= 0.18, 95%CI=0.10-0.33, P<0.001). In the multivariable logistic regression model, adjustments were sequentially made for gender, age, left atrial dimension, CHA₂DS₂-VAS_C score and ablation strategy grouping. Even after these adjustments, the benefits persisted, with UV (OR= 0.11, 95%CI=0.06-0.20, P<0.001) consistently outperforming BV (OR= 0.22, 95%CI=0.09-0.31, P<0.001).

Multivariable logistic regressions were performed with UV and BV, respectively, and predictive models for UV and BV were established separately. UV (OR=0.11, 95%CI=0.06-0.19, p<0.001) (Table 5) and BV (OR=0.16, 95%CI=0.09-0.29, P<0.001) (Table 6) were discovered to be independently associated with AF recurrence and can establish their own model. The BV or UV from the CPVI alone/CPVI plus group was set as the independent variables to create two prediction models. The predict precision of the two models was then compared.

The ROC analysis was used to investigate the discrimination of the prediction model. The AUC was 0.757 (95% CI:0.699-0.815) and 0.858 (95%CI:0.809-0.907) for BV and UV, and

205 the difference in AUC values is statistically significant (P<0.001), respectively (Figure 1).

The calibration plots revealed good predictive accuracy between the actual probability and predicted probability of recurrence. The Hosmer and Lemeshow test showed an effective goodness-of-fit in both the BV model (P=0.219, MAE=0.029) (Figure 2A) and the UV model (P=0.3722, MAE=0.02) (Figure 2B).

210 The decision curve analysis showed that the BV predicting model had a positive net benefit

211	for a threshold probability between 0% and 45%. The UV predicting model has a better net
212	benefit between 0% and 70% compared to BV predicting model (Figure 3).

213 Subgroup study

We then performed a subgroup analysis to explore the efficacy of predicting recurrence with BV and UV in the two subgroups of CPVI alone and CPVI plus (Supplement Table 2). The AUC was 0.751 (95% CI: 0.673-0.829) for BV and 0.843 (95% CI: 0.773-0.913) for UV in the CPVI alone cohort, and the difference between AUC values is statistically significant (P=0.0008), respectively (Figure 4A). In the meantime, the AUC was 0.750 (95% CI: 0.659–

219 0.841) for BV and 0.882 (95% CI: 0.809–0.954) for UV in CPVI plus cohort, and the difference

220 between AUC values is statistically significant (P=0.0004), respectively (Figure 4B). The

- 221 Hosmer and Lemeshow test of the UV model showed an effective goodness-of-fit both in CPVI
- alone cohorts(P=0.5471) (Figure 4C) and CPVI plus cohorts(P=0.3779) (Figure 4D). The
- 223 Hosmer and Lemeshow test of BV model showed an effective goodness-of-fit both in CPVI

alone cohorts(P=0.052) (Figure 4E) and CPVI plus cohorts(P=0.2132) (Figure 4F).

225

226 **Discussions**

227 Major finds

In this post-hoc analysis of the STABLE-SR III trial, we investigated and compared the predictive efficacy of the mean LA UV vs BV for recurrent ATa after AF ablation in elderly paroxysmal AF patients. Our main findings include: (1) Both the mean unipolar and bipolar left atrial voltage serve as risk indicators for ATa events after AF ablation. However, only the mean UV is independently associated with the long-term freedom from ATa. (2) The predictive value of UV for recurrence is significantly superior to that of BV, as demonstrated by the model

234 developed through multivariable analysis. These results underscore the advantages of unipolar

235 mapping in characterizing the comprehensive three-dimensional substrate pattern.

236 Role of unipolar vs bipolar voltage in detecting atrial fibrosis

Myocardial fibrosis plays a crucial role in the cardiac remodeling observed in individuals 237 with AF². Cardiac fibroblasts transmit electrical currents between myocardial cells through 238 connecting proteins, resulting in uneven current conduction, slowed conduction velocity, 239 shortened action potential and increased conduction heterogeneity -- all of which can be 240 reflected in the intracardiac electrograms obtained through contact mapping¹²⁻¹⁶. Deneke T et 241 al. were the first to demonstrate a histopathological correlation of BV mapping in identifying 242 the ventricular arrhythmic substrate¹⁷. Although several studies have highlighted the utility of 243 bipolar recording in detecting endocardial and epicardial scars in both ischemic and non-244 245 ischemic cardiomyopathy, inconsistency between BV and the transmural extent of infraction has been reported. This discrepancy calls into question the "field of view" of bipolar 246 electrograms^{9, 10, 18}. An elegant study introduced UV mapping and demonstrated its superiority 247 in characterizing transmural substrate features in non-ischemic cardiomyopathy⁹. 248

The human atrial wall is a thin structure, with average measurements of wall thickness between 1 and 4 mm but with a broader range extending from 0.5 to 12 mm¹⁹. Furthermore, several studies have provided evidence for endocardial-epicardial voltage and activation asynchrony in patients with $AF^{8, 18, 20, 21}$. BV, with its detection range limited to the endocardium or sub-endocardium -- sometimes within 1-2 mm deep layers, might not be optimal for capturing the complete substrate features of the entire layer. Consequently, UV mapping might also hold an advantage in reflecting three-dimensional substrate information in atrium. In the

present study, for the first time, the efficacy of UV in predicting the recurrence of ATa after 256 catheter ablation was demonstrated to be superior to that of BV. Admittedly, in univariable 257 analysis, both UV and BV correlated with the long-term freedom of ATa. However, in 258 multivariable analysis, the association between BV and outcome was overshadowed by the 259 stronger link between UV and outcome. Furthermore, the model developed based on the UV 260 demonstrated a larger area under the ROC for predicting the ATa recurrence compared to BV. 261 Theoretically, this statistical superiority can only be attributed to the previously mentioned the 262 wider "field of view" of UV for deeper substrates. 263

It's worth noting that the superiority of UV over BV for predicting recurrence exists regardless of whether patients receiving substrate modification, which is in line with the findings in DECAFF study. In DECAFF-II trial, atrial fibrosis detected by MRI, which is also a comprehensive approach, is similar to our UV assessment and shares the analogues predictive value in predicting the AF recurrence.

269 Clinical implications

270 To quantify atrial fibrosis in AF patients who underwent ablation is of clinical importance. Firstly, it aids in identifying those patients who were most likely to benefit from the procedure. 271 In DECAAF studies, severer atrial fibrosis has been proven to be a significant predictor for 272 ablation failure. Cardiac magnetic resonance imaging (CMRI) showed potential utility in 273 evaluating atrial fibrosis^{14, 16}. However, this technique has not been widely adopted, and CMRI 274 is time-consuming and not readily available. BV during the ablation procedure is often adopted 275 as a simple and convenient tool to predict the long-term outcomes. Herein, we have developed 276 a model integrating the unipolar and clinical parameters as a more powerful tool compared to 277

BV. Whether the plus LVA modification was performed or not, the mean left atrium UV of 278 2.82±1.10mV provided a C-index of 0.858 (95%CI:0.809-0.907). Another potential application 279 280 scenario of the UV mapping for AF ablation is the patient-tailored ablation approach based on the LVA. To date, there is inconsistency regarding the benefits of fibrosis-targeting ablation 281 approach^{7, 16, 22}. The DECAFF study demonstrated no significant difference in terms of ATa 282 recurrence between the CMRI-guided fibrosis ablation plus PVI and PVI only^{14, 16}. However, 283 other studies, including STABLE-SR-III, have shown positive results^{7, 22}. The discrepancy in 284 fibrosis identification methods may contribute to this inconsistency. We have long observed a 285 discordance between CMRI-based fibrosis assessment and that of LVA assessed by bipolar 286 recording. In the DECAFF series, nearly half of the patients were categorized as stage 3 or 287 stage 4 (at least 20% of the atrial wall has fibrosis), while in STABLE-SR series, only about 288 10% patients had >10% of the atrial wall identified as confluent LVA^{5-7, 14, 16}. We speculate that 289 the limited "field of view" by bipolar mapping partly contributes to this discordance. In the 290 future, it seems reasonable and promising to employ the UV-based LVA as the surrogate for 291 292 fibrosis during this patient-tailored ablation strategy.

293

294 Limitations

As a post-hoc analysis of the STABLE-SR-III research, is inevitably constrained by the inclusion criteria, specifically focusing on data from elderly patients with paroxysmal AF. Consequently, the findings cannot be readily extrapolated to the entire population. Furthermore, the study did not explore the determination of precise UV cutoff value to standardize the lowvoltage area and discuss its relationship with prognosis.

300	
301	Conclusion
302	The endocardial mean UV of LA demonstrates a higher predictive value for predicting
303	recurrence after ablation compared to mean BV in elderly patients with AF. The superiority of
304	unipolar mapping in predicting recurrence implicates its advantage of providing a broader,
305	more penetrative field of view to identify arrhythmogenic substrates in deeper layers of the
306	atrium.
307	
308	Acknowledgement
309	We thank all patients for participating in this study and all clinicians for their invaluable
310	assistance in the evaluation of mapping data and clinical assessments.
311	
312	Source of funding
313	This study was supported by Special Foundation for Clinical Science and Technology of
314	Jiangsu Province (BE2017754), Department of Science and Technology of Guangdong
315	Province(2019B020230004), and the National Natural Science Foundation of China (General
316	Program,82370322).
317	
318	Disclosures
319	All authors have completed and submitted the Conflicts of Interest Statement. Dr. Chen
320	reports receiving lecture fee from Biosense Webster, St. Jude Medical, Medtronic, Bayer and
321	Boehringer Ingelheim. No other disclosures were reported.

322

323 Supplement material

324 Table S1, S2

325 **References**

- Brundel BJJM, Ai X, Hills MT, Kuipers MF, Lip GYH, de Groot NMS. Atrial
 fibrillation. *Nat Rev Dis Primers*. 2022;8:21
- Sohns C, Marrouche NF. Atrial fibrillation and cardiac fibrosis. *Eur Heart J.* 2020;41:1123-1131
- 3. Nattel S. Molecular and cellular mechanisms of atrial fibrosis in atrial fibrillation.
 JACC Clin Electrophysiol. 2017;3:425-435
- 332 4. Xintarakou A, Tzeis S, Psarras S, Asvestas D, Vardas P. Atrial fibrosis as a dominant
 333 factor for the development of atrial fibrillation: Facts and gaps. *Europace*. 2020;22:342334 351
- 5. Yang B, Jiang C, Lin Y, Yang G, Chu H, Cai H, et al. Stable-sr (electrophysiological substrate ablation in the left atrium during sinus rhythm) for the treatment of nonparoxysmal atrial fibrillation: A prospective, multicenter randomized clinical trial. *Circ Arrhythm Electrophysiol*. 2017;10
- Kang G, Zheng L, Jiang C, Fan J, Liu X, Zhan X, et al. Circumferential pulmonary vein
 isolation plus low-voltage area modification in persistent atrial fibrillation: The stablesr-ii trial. *JACC Clin Electrophysiol*. 2022;8:882-891
- Chen H, Li C, Han B, Xiao F, Yi F, Wei Y, et al. Circumferential pulmonary vein isolation with vs without additional low-voltage-area ablation in older patients with paroxysmal atrial fibrillation: A randomized clinical trial. *JAMA Cardiol*. 2023;8:765-772
- Yavin H, Younis A, Zilberman I, Krywanczyk A, Bubar ZP, Higuchi K, et al. Atrial
 endocardial unipolar voltage mapping for detection of viable intramural myocardium:
 A proof-of-concept study. *Circ Arrhythm Electrophysiol*. 2023;16:e011321
- 349
 9. Campos B, Jauregui ME, Park K-M, Mountantonakis SE, Gerstenfeld EP, Haqqani H,
 350 et al. New unipolar electrogram criteria to identify irreversibility of nonischemic left
 351 ventricular cardiomyopathy. *J Am Coll Cardiol*. 2012;60:2194-2204
- Hoogendoorn JC, Venlet J, de Riva M, Wijnmaalen AP, Piers SRD, Zeppenfeld K.
 Unipolar voltage mapping in right ventricular cardiomyopathy: Pitfalls, solutions and advantages. *Europace*. 2023;25:1035-1040
- Nairn D, Lehrmann H, Müller-Edenborn B, Schuler S, Arentz T, Dössel O, et al.
 Comparison of unipolar and bipolar voltage mapping for localization of left atrial
 arrhythmogenic substrate in patients with atrial fibrillation. *Front Physiol.*2020;11:575846
- Hansen BJ, Zhao J, Fedorov VV. Fibrosis and atrial fibrillation: Computerized and
 optical mapping; a view into the human atria at submillimeter resolution. *JACC Clin Electrophysiol.* 2017;3:531-546
- Ma J, Chen Q, Ma S. Left atrial fibrosis in atrial fibrillation: Mechanisms, clinical
 evaluation and management. *J Cell Mol Med*. 2021;25:2764-2775
- Marrouche NF, Wazni O, McGann C, Greene T, Dean JM, Dagher L, et al. Effect of
 mri-guided fibrosis ablation vs conventional catheter ablation on atrial arrhythmia
 recurrence in patients with persistent atrial fibrillation: The decaaf ii randomized
 clinical trial. *JAMA*. 2022;327:2296-2305

- Schotten U, Verheule S, Kirchhof P, Goette A. Pathophysiological mechanisms of atrial
 fibrillation: A translational appraisal. *Physiol Rev.* 2011;91:265-325
- Marrouche NF, Wilber D, Hindricks G, Jais P, Akoum N, Marchlinski F, et al.
 Association of atrial tissue fibrosis identified by delayed enhancement mri and atrial
 fibrillation catheter ablation: The decaaf study. *JAMA*. 2014;311:498-506
- 17. Deneke T, Müller K-M, Lemke B, Lawo T, Calcum B, Helwing M, et al. Human
 histopathology of electroanatomic mapping after cooled-tip radiofrequency ablation to
 treat ventricular tachycardia in remote myocardial infarction. *J Cardiovasc Electrophysiol*. 2005;16:1246-1251
- Tokuda M, Tedrow UB, Inada K, Reichlin T, Michaud GF, John RM, et al. Direct
 comparison of adjacent endocardial and epicardial electrograms: Implications for
 substrate mapping. *J Am Heart Assoc.* 2013;2:e000215
- Whitaker J, Rajani R, Chubb H, Gabrawi M, Varela M, Wright M, et al. The role of
 myocardial wall thickness in atrial arrhythmogenesis. *Europace*. 2016;18:1758-1772
- de Groot N, van der Does L, Yaksh A, Lanters E, Teuwen C, Knops P, et al. Direct proof
 of endo-epicardial asynchrony of the atrial wall during atrial fibrillation in humans. *Circ Arrhythm Electrophysiol.* 2016;9
- Seewöster T, Marinov K, Löbe S, Knopp H, Nedios S, Bollmann A, et al. Abnormal
 pattern of left atrial activation and asynchronous conduction predicted the occurrence
 of new atrial fibrillation: Evidences for bachmann's bundle block in atrial fibrillation
 pathophysiology. *Europace*. 2021;23:1244-1251
- Huo Y, Gaspar T, Schönbauer R, Wójcik M, Fiedler L, Roithinger FX, et al. Low voltage myocardium-guided ablation trial of persistent atrial fibrillation. *NEJM Evidence*. 2022;1
- 392
- 393

394 Table 1

395 Baseline characteristics

Characteristic	Total ($n = 375$)
Age, Mean ± SD	70.41 ± 4.28
AF duration, Mean ± SD	39.35 ± 59.07
BMI, Mean ± SD	24.36 ± 3.26
LAD mm, Mean ± SD	38.80 ± 5.37
LVEF %, Mean ± SD	62.21 ± 5.25
LVA burden, Mean \pm SD	3.13 ± 6.72
GENDER	
Female	180(48)
Male	195(52)
BMI grade, n (%)	
<25	222 (61.84)
≥25	137 (38.16)
Comorbidities, n (%)	
HBP	239 (63.73)
T2DM	71(18.93)
CAD	88 (23.47)
Stroke, TIA	36(9.6)
COPD	11(2.93)
OSAS	8(2.13)
NYHA, n (%)	
1	347 (96.93)
2	10 (2.79)
3	1 (0.28)
CHA2DS2 VA score, n (%)	
0	17 (4.53)
1	131 (34.93)

Characteristic	Total $(n = 375)$
2	146 (38.93)
3	59 (15.73)
4	18 (4.8)
5	4 (1.07)
Medication use, n (%)	
Class I AAD	68 (18.13)
Class III AAD	112 (29.87)
ACEI or ARB	108 (28.8)
Beta blocker	124 (33.07)
CCB	60 (16)
Digoxin	3 (0.8)
LVA burden grade, n (%)	
0	209 (55.73)
1	133 (35.47)
2	21 (5.6)
3	12 (3.2)
Bipolar (mV), Mean ± SD	1.50 ± 0.55
Unipolar (mV), Mean ± SD	2.82 ± 1.10
Points, Mean ± SD	198.46 ± 114.97

AF, atrial fibrillation; BMI, body mass index; LAD, left atrial diameter; LVEF, left ventricular ejection
fraction; LVA burden, low voltage area burden; HBP, high blood pressure; T2DM, diabetes mellitus type 2;
CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; OSAS, obstructive sleep
apnea syndrome; TIA, transient ischemic attack; CPVI plus, circumferential pulmonary vein isolation plus
additional LVA ablation; CPVI alone, only do CPVI without additional ablation

Table 2 402

Univariate logistic regression 403

404

Characteristics	β	OR (95%CI)	Р
Unipolar	-2.16	0.12 (0.07 - 0.21)	<.001
Bipolar	-1.76	0.18 (0.10 - 0.33)	<.001
LVA burden	0.05	1.05 (1.02 - 1.09)	0.003
Group			
CVPI alone		1.00 (Reference)	
CPVI plus	-0.70	0.49(0.27 - 0.92)	0.026

LAD, left atrial diameter; LVA burden, low voltage area burden; CPVI plus, circumferential pulmonary vein 405

isolation plus additional LVA ablation; CPVI alone, only do CPVI without additional ablation; OR, odds 406 407 ratio

Table 3

Multivariable logistic regression

Characteristics	β	OR (95%CI)	Р
Unipolar	-2.14	0.12 (0.06 - 0.25)	<.001
Bipolar	-0.14	0.87 (0.35 - 2.14)	0.755
LVA burden	-0.00	1.00 (0.96 - 1.04)	0.906
Group			
CVPI alone		1.00 (Reference)	
CPVI plus	-0.71	0.49(0.26 - 0.92)	0.026

Table 4 413

Freedom from atrial tachyarrhythmia recurrence of Bipolar voltage and Unipolar 414

- voltage adjusted for clinical features 415
- 416

	Model	1	Model	2	Model	3	Model 4	4
Variables					· · · · · · · · · · · · · · · · · · ·	-		
	OR (95%CI)	Р	OR (95%CI)	Р	OR (95%CI)	Р	OR (95%CI)	Р
Binolar	0.18 (0.10 -	<.001	0.17 (0.09 -	<.001	0.21 (0.09 -	<.001	0.22 (0.09 -	<.001
Dipolai	0.33)		0.33)		0.32)		0.31)	
	0.12 (0.07 -	0.04	0.12 (0.06 -	0.04	0.11 (0.06 -	0.0.1	0.11 (0.06 -	0.0.4
Unıpolar	0.21)	<.001	0.21)	<.001	0.20)	<.001	0.20)	<.001

OR: Odds Ratio; CI: Confidence Interval, LAD, left atrial diameter; Group: CPVI plus and CPVI alone group; CPVI plus: circumferential pulmonary vein isolation plus additional LVA ablation; CPVI alone, only do CPVI without additional ablation;

Model 1: unadjusted model

Model 2: adjusted for Age, Gender

Model 3: adjusted for Model 2 covariates plus LAD, CHA2DS2-VA score

Model 4: adjusted for Model 3 covariates plus ablation strategy feature

Table 5 418

Multivariable logistic regression for Unipolar model 419

420

Characteristics	β	OR (95%CI)	Р
Unipolar	-2.21	0.11 (0.06 - 0.19)	< 0.001
Group			
CPVI plus		1.00 (Reference)	
CPVI alone	-0.70	0.50(0.27 - 0.92)	0.027

CPVI plus, circumferential pulmonary vein isolation plus additional LVA ablation; CPVI alone, only do 421

CPVI without additional ablation; OR, odds ratio 422

Table 6 424

Multivariable logistic regression for Bipolar model 425

426

Characteristics	β	OR (95%CI)	Р
Bipolar	-1.84	0.16 (0.09 - 0.29)	< 0.001
Group			
CPVI alone		1.00 (Reference)	
CPVI plus	-0.65	0.52 (0.30 - 0.92)	0.023

CPVI plus, circumferential pulmonary vein isolation plus additional LVA ablation; CPVI alone, only do 427

CPVI without additional ablation; OR, odds ratio 428

430 Figure legend

431

432 Figure 1

433

434 ROC for models in predicting recurrence in elder patients. ROC curve of bipolar and
435 unipolar voltage models; The orange line shows the ROC for unipolar voltage, the blue line
436 shows the ROC for bipolar voltage. AUC: area under the curve.

- 438 Figure 2
- 439

437

The Hosmer—Lemeshow calibration curve for the model predicting probability of
recurrence in elder AF patients. (A) Calibration curve for the bipolar voltage model. (B)
Calibration curve for the unipolar voltage model. X-axis is predicted probability by model and
y-axis is actual probability.

- 444
- 445 Figure 3446

447 The decision curve analysis (DCA) for the model predicting probability of AF recurrence in elder AF patients. All the decision curve of the prediction models are composed of an X-448 axis which represents continuum of potential thresholds for risk and a Y-axis which represents 449 the net benefit which is obtained by dividing the net true positives by the sample size. In the 450 figure, the red curve "Treat ALL" shows the net benefit if all elder AF patients were intervened 451 for bipolar or unipolar voltage. The green line "Treat None" shows the net benefit if no elder 452 AF patients were intervened for bipolar or unipolar voltage. The blue and yellow line 453 "prediction model for unipolar and bipolar voltage" curve shows the net benefit if it is used to 454 select patients for intervention. 455

456

457 **Figure 4**

458

459 ROC for models in predicting AF recurrence in subgroup study. (A) ROC curve for the bipolar and unipolar voltage models in the CPVI alone group; (B) ROC curve for the bipolar 460 and unipolar voltage models in the CPVI plus group. In both figures, the blue line shows the 461 ROC for unipolar voltage, the yellow line shows the ROC for bipolar voltage. AUC: area under 462 the curve. The Hosmer-Lemeshow calibration curve for the model predicting probability of 463 recurrence in elder AF patients. (C) Calibration curve for the unipolar voltage model in the 464 CPVI alone group. (D) Calibration curve for the unipolar voltage model in the CPVI plus group. 465 (E) Calibration curve for the bipolar voltage model in the CPVI alone group. (F) Calibration 466 curve for the bipolar model in the CPVI plus group. X-axis is predicted probability by model 467 and y-axis is actual probability of recurrence. 468

469



1 - Specificity







Low unipolar voltage demonstrates more powerful predictive value compare with bipolar voltage



Bipolar and Unipolar voltage predictive value for recurrence of AT/AF



Decision curve analysis for unipolar and bipolar predict recurrence models



Table 1Baseline characteristics

Characteristic	Total ($n = 375$)
Age, Mean ± SD	70.41 ± 4.28
AF duration, Mean \pm SD	39.35 ± 59.07
BMI, Mean \pm SD	24.36 ± 3.26
LAD mm, Mean ± SD	38.80 ± 5.37
LVEF %, Mean ± SD	62.21 ± 5.25
LVA burden, Mean \pm SD	3.13 ± 6.72
GENDER	
Female	180(48)
Male	195(52)
BMI grade, n (%)	
<25	222 (61.84)
≥25	137 (38.16)
Comorbidities, n (%)	
HBP	239 (63.73)
T2DM	71(18.93)
CAD	88 (23.47)
Stroke, TIA	36(9.6)
COPD	11(2.93)
OSAS	8(2.13)
NYHA, n (%)	
1	347 (96.93)
2	10 (2.79)
3	1 (0.28)

Characteristic	Total (<i>n</i> = 375)
CHA2DS2 VA score, n (%)	
0	17 (4.53)
1	131 (34.93)
2	146 (38.93)
3	59 (15.73)
4	18 (4.8)
5	4 (1.07)
Medication use, n (%)	
Class I AAD	68 (18.13)
Class III AAD	112 (29.87)
ACEI or ARB	108 (28.8)
Beta blocker	124 (33.07)
CCB	60 (16)
Digoxin	3 (0.8)
LVA burden grade, n (%)	
0	209 (55.73)
1	133 (35.47)
2	21 (5.6)
3	12 (3.2)
Bipolar (mV), Mean ± SD	1.50 ± 0.55
Unipolar (mV), Mean ± SD	2.82 ± 1.10
Points, Mean ± SD	198.46 ± 114.97

AF, atrial fibrillation; BMI, body mass index; LAD, left atrial diameter; LVEF, left ventricular ejection fraction; LVA burden, low voltage area burden; HBP, high blood pressure; T2DM, diabetes mellitus type 2; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; OSAS, obstructive sleep apnea syndrome; TIA, transient ischemic attack; CPVI plus, circumferential pulmonary vein isolation plus additional LVA ablation; CPVI alone, only do CPVI

without additional ablation

Characteristics	β	OR (95%CI)	Р
Unipolar	-2.16	0.12 (0.07 - 0.21)	<.001
Bipolar	-1.76	0.18 (0.10 - 0.33)	<.001
LVA burden	0.05	1.05 (1.02 - 1.09)	0.003
Group			
CVPI alone		1.00 (Reference)	
CPVI plus	-0.70	$0.49\ (0.27 - 0.92)$	0.026

Table 2 Univariate logistic regression

LAD, left atrial diameter; LVA burden, low voltage area burden; CPVI plus, circumferential pulmonary vein isolation plus additional LVA ablation; CPVI alone, only do CPVI without additional ablation; OR, odds ratio

Table 3		
Multivariable	logistic	regression

Characteristics	β	OR (95%CI)	Р
Unipolar	-2.14	0.12 (0.06 - 0.25)	<.001
Bipolar	-0.14	0.87 (0.35 - 2.14)	0.755
LVA burden	-0.00	1.00 (0.96 - 1.04)	0.906
Group			
CVPI alone		1.00 (Reference)	
CPVI plus	-0.71	0.49 (0.26 - 0.92)	0.026

Table 4

Freedom from atrial tachyarrhythmia recurrence of Bipolar voltage and Unipolar voltage adjusted for clinical features

	Model	1	Model	2	Model	3	Model	4
Variables	OR	D	OR	D	OR	D	OR	D
	(95%CI)	P	(95%CI)	P	(95%CI)	P	(95%CI)	Р
	0.18 (0.10 -		0.17 (0.09 -		0.21 (0.09 -		0.22 (0.09 -	
Bıpolar	0.33)	<.001	0.33)	<.001	0.32)	<.001	0.31)	<.001
	0.12 (0.07 -		0.12 (0.06 -		0.11 (0.06 -		0.11 (0.06 -	
Unipolar	0.21)	<.001	0.21)	<.001	0.20)	<.001	0.20)	<.001

OR: Odds Ratio; CI: Confidence Interval, LAD, left atrial diameter; Group: CPVI plus and CPVI alone group; CPVI plus: circumferential pulmonary vein isolation plus additional LVA ablation; CPVI alone, only do CPVI without additional ablation;

Model 1: unadjusted model

Model 2: adjusted for Age, Gender

Model 3: adjusted for Model 2 covariates plus LAD, CHA2DS2-VA score

Model 4: adjusted for Model 3 covariates plus ablation strategy feature

Characteristics	β	OR (95%CI)	Р
Unipolar	-2.21	0.11 (0.06 – 0.19)	< 0.001
Group			
CPVI plus		1.00 (Reference)	
CPVI alone	-0.70	0.50(0.27 - 0.92)	0.027

Table 5 Multivariable logistic regression for Unipolar model

CPVI plus, circumferential pulmonary vein isolation plus additional LVA ablation; CPVI alone, only do CPVI without additional ablation; OR, odds ratio

Characteristics	β	OR (95%CI)	Р
Bipolar	-1.84	0.16 (0.09 - 0.29)	< 0.001
Group			
CPVI alone		1.00 (Reference)	
CPVI plus	-0.65	0.52 (0.30 - 0.92)	0.023

Table 6 Multivariable logistic regression for Bipolar model

CPVI plus, circumferential pulmonary vein isolation plus additional LVA ablation; CPVI alone, only do CPVI without additional ablation; OR, odds ratio